Ocular Therapeutix may have found a new way to increase patient compliance via tiny hydrogel plugs. The phase II trial for patients being treated with ocular hypertension and glaucoma will be conducted in South Africa and enroll 20 patients. These tiny degradable tear drainage ducts deliver medication directly to the eye over the course of several months. This will ultimately eliminate the inconvenience of daily drops.
"This has been the holy grail of ophthalmology for along period of time, to find a way to be able to tackle chronic long-term diseases like glaucoma," president & CEO Amar Sawhney said. Extending treatment duration for the disease is a key milestone for our company's path to commercialization. If the study progresses, which Pharma companies will be most likely to jump on board first?
At Drug Delivery Partnerships, dozens of established and novel drug delivery technology companies like Ocular Therapeutix join hundreds of pharmaceutical and drug delivery thought leaders to develop partnerships to create the next great product that will bring relief to millions of patients. Sign up for updates on the 17th Annual Drug Delivery Partnerships Conference taking place February 6-8, 2012, in San Diego, CA.